Strong Buy
Average AnalystStrong Buy
Top AnalystNeutral
Stock Target AdvisorBuy
Average UserUSD 203.55
0.00 (0.00)%
USD 359.54B
4.49M
USD 204.00(+0.22%)
Symbol | Name | Exchange | ABBV's Weight | Expense Ratio | Price(Change) | Market Cap |
---|---|---|---|---|---|---|
|
First Trust Nasdaq Pharma.. | NSD | 7.27 % | 0.60 % | 0.00 (0.00%) | USD0.02B |
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.